Lotus Pharmaceutical Co., Ltd. (TPE:1795)

-28.45% (1Y)

Market Cap	56.28B
Revenue (ttm)	19.12B
Net Income (ttm)	5.46B
Shares Out	261.75M
EPS (ttm)	20.73
PE Ratio	10.37
Forward PE	10.78
Dividend	5.73 (2.67%)
Ex-Dividend Date	Aug 5, 2024

Volume	630,952
Average Volume	905,263
Open	212.50
Previous Close	214.00
Day's Range	212.50 - 216.00
52-Week Range	172.50 - 294.50
Beta	-0.06
RSI	43.29
Earnings Date	Aug 7, 2025

About Lotus Pharmaceutical

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1966
• Employees: 1,099
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1795

Financial Performance

In 2024, Lotus Pharmaceutical's revenue was 18.58 billion, an increase of 9.59% compared to the previous year's 16.96 billion. Earnings were 5.07 billion, an increase of 23.38%.